Video
Dr. Ketan K. Badani on how genomic tests help facilitate patient discussions
Author(s):
“One of the toughest parts about having a discussion with a patient about low-risk or early-stage prostate cancer…is actually deciding what might be best for that individual patient,” says Ketan K. Badani, MD.
Video Player is loading.
In this video, Ketan K. Badani, MD, discusses how genomic tests such as Oncotype DX help him discuss treatment options for patients with low-risk or early-stage prostate cancer. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.
Related Videos
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Related Content
